<DOC>
	<DOCNO>NCT01474863</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , phase 2 study evaluate biochemical , clinical , safety effect 2 dos intravenous L-citrulline compare placebo patient severe sepsis risk acute lung injury . The hypothesis intravenous L-citrulline decrease development progression acute lung injury patient severe sepsis compare placebo .</brief_summary>
	<brief_title>Citrulline Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<criteria>Severe Sepsis No Consent Malignant irreversible condition Moribund expect survive 48 hour End Stage Liver Disease Enrolled another IND study Pregnant breast feed female Age &lt; 13 year old Allergy citrulline arginine</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>